◼ Archived
Business
🔮 fades ✓
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
A $7.8 billion Chinese biotech pact flips the script on Western pharma’s mRNA playbook.
Novartis
18 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Novartis
This hub groups 18 separate news trends connected to Novartis, spanning July 6, 2026 through October 2, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 130 article observations and 123 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's Sefaxersen hits target in late-stage study for autoimmune disease
◼ Archived
Business
🔮 fades ✓
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis’s $900 million BoomRay radioligand deal spotlights a China-origin, preclinical asset amid mounting competition in the biotech field
◼ Archived
Business
🔮 fades ✓
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix’s high‑profile ITM acquisition, variably reported at $1.65 billion or $2.35 billion, fuels bullish analyst sentiment and a clash over deal figures
◼ Archived
Business
🔮 fades ✓
Novartis’ TREM2 drug fails Phase 2 ALS trial
Novartis' ALS drug fails in mid-stage trial, halting development
◼ Archived
Business
🔮 fades ✓
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis faces activist pressure as a major shareholder demands board changes after a costly drug trial failure.
◼ Archived
Business
🔮 fades ✓
Novartis’s Latest Trial Setback Sinks Stock
Novartis’s stock tumbles as a second Phase III failure shatters hopes for its Avidity acquisition.
◼ Archived
Business
🔮 fades ✓
Novartis cholesterol setback tests hopes for emerging heart disease drugs
Novartis' cholesterol drug fails critical cardiovascular test, casting doubt on multibillion-dollar heart disease drug race.
◼ Archived
Business
🔮 fades ✓
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Novartis' experimental heart drug Pelacarsen has failed a pivotal study, disappointing investors and cardiologists.
◼ Archived
Business
🔮 fades ✓
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis secures a high-stakes subcutaneous delivery agreement with Alteogen, shifting industry dynamics and drawing varied market reactions.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
🔮 holds ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.
◼ Archived
Business
🔮 fades ✓
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
◼ Archived
Business
🔮 fades ✓
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers have paused CAR-T trials after patient deaths, raising safety concerns in the biopharma industry.
◼ Archived
Health
🔮 fades ✓
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
Novartis’s IL‑6 blocker Pacibekitug slashes inflammation markers for half a year, sparking debate over its heart‑benefit potential.
◼ Archived
Health
🔮 fades ✓
A close look at the new cholesterol guidelines, plus the role of diet
New cholesterol guidelines are out, and they may change how you manage your heart health.
◼ Archived
Business
🔮 fades ✓
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA's rejection of ITM's radiopharma therapy sends shockwaves through the pharmaceutical industry.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.